The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Pfizer

Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
 
Christie Zettler
Consulting or Advisory Role - Rabin Martin (Inst)
 
Dilanka De Silva
No Relationships to Disclose
 
Victoria Susana Blinder
No Relationships to Disclose
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst)
Other Relationship - Clinical Care Options; Clinical Education Alliance; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Elena B. Elkin
No Relationships to Disclose